HDAC5

Summary

HDAC5 (histone deacetylase 5, HGNC:14068) is a protein-coding gene on chromosome 17q21.31, encoding Histone deacetylase 5 (Q9UQL6). Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).

Histones play a critical role in transcriptional regulation, cell cycle progression, and developmental events. Histone acetylation/deacetylation alters chromosome structure and affects transcription factor access to DNA. The protein encoded by this gene belongs to the class II histone deacetylase/acuc/apha family. It possesses histone deacetylase activity and represses transcription when tethered to a promoter. It coimmunoprecipitates only with HDAC3 family member and might form multicomplex proteins. It also interacts with myocyte enhancer factor-2 (MEF2) proteins, resulting in repression of MEF2-dependent genes. This gene is thought to be associated with colon cancer. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 10014 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 12
• Clinical variants (ClinVar): 173 total
• Druggable target: yes — 30 molecules with ChEMBL bioactivity
• Transcription factor: yes — 10 downstream targets (CollecTRI)
• MANE Select transcript: NM_005474

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14068
Approved symbol	HDAC5
Name	histone deacetylase 5
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0600, NY-CO-9, FLJ90614
Ensembl gene	ENSG00000108840
Ensembl biotype	protein_coding
OMIM	605315
Entrez	10014

Gene structure

Transcript identifiers

Ensembl transcripts: 64 — 59 protein_coding, 5 retained_intron

ENST00000225983, ENST00000336057, ENST00000586339, ENST00000586802, ENST00000587135, ENST00000587776, ENST00000588261, ENST00000588419, ENST00000588703, ENST00000591714, ENST00000592385, ENST00000593013, ENST00000682912, ENST00000715273, ENST00000864900, ENST00000864901, ENST00000864902, ENST00000864903, ENST00000864904, ENST00000864905, ENST00000864906, ENST00000864907, ENST00000864908, ENST00000864909, ENST00000864910, ENST00000864911, ENST00000864912, ENST00000864913, ENST00000864914, ENST00000864915, ENST00000864916, ENST00000864917, ENST00000864918, ENST00000864919, ENST00000864920, ENST00000864921, ENST00000864922, ENST00000864923, ENST00000864924, ENST00000864925, ENST00000925825, ENST00000925826, ENST00000925827, ENST00000925828, ENST00000925829, ENST00000925830, ENST00000925831, ENST00000925832, ENST00000968358, ENST00000968359, ENST00000968360, ENST00000968361, ENST00000968362, ENST00000968363, ENST00000968364, ENST00000968365, ENST00000968366, ENST00000968367, ENST00000968368, ENST00000968369, ENST00000968370, ENST00000968371, ENST00000968372, ENST00000968373

RefSeq mRNA: 3 — MANE Select: NM_005474 NM_001015053, NM_001382393, NM_005474

CCDS: CCDS32663, CCDS45696

Canonical transcript exons

ENST00000682912 — 27 exons

Exon	Start	End
ENSE00000731166	44080763	44080882
ENSE00000731172	44079144	44079277
ENSE00000731173	44078795	44078879
ENSE00000731174	44078500	44078665
ENSE00001619144	44093575	44093834
ENSE00001669662	44093314	44093485
ENSE00001711158	44110729	44110800
ENSE00001724889	44092172	44092284
ENSE00001739338	44080107	44080225
ENSE00002261772	44117494	44117704
ENSE00002350210	44080401	44080498
ENSE00002425474	44082585	44082672
ENSE00003478670	44091700	44091831
ENSE00003482191	44088387	44088598
ENSE00003484375	44085022	44085155
ENSE00003521425	44087412	44087696
ENSE00003533985	44092676	44092806
ENSE00003562125	44083545	44083652
ENSE00003586612	44086572	44086737
ENSE00003605327	44084555	44084675
ENSE00003622443	44082765	44082820
ENSE00003650856	44092381	44092527
ENSE00003653051	44083805	44083854
ENSE00003666410	44091270	44091492
ENSE00003691295	44093092	44093206
ENSE00003918270	44076753	44078415
ENSE00003921347	44123504	44123641

Expression profiles

Bgee: expression breadth ubiquitous, 240 present calls, max score 97.07.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 31.1749 / max 773.4901, expressed in 1816 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
166311	15.8474	1796
166310	12.7901	1744
166307	1.9301	806
166306	0.2162	107
166304	0.1551	71
166309	0.1258	59
166303	0.1101	56

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	97.07	gold quality
lower esophagus mucosa	UBERON:0035834	96.61	gold quality
skin of leg	UBERON:0001511	96.59	gold quality
skin of abdomen	UBERON:0001416	96.42	gold quality
ganglionic eminence	UBERON:0004023	96.29	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.96	gold quality
right frontal lobe	UBERON:0002810	95.87	gold quality
popliteal artery	UBERON:0002250	95.78	gold quality
tibial artery	UBERON:0007610	95.77	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.74	gold quality
apex of heart	UBERON:0002098	95.68	gold quality
cerebellar hemisphere	UBERON:0002245	95.48	gold quality
aorta	UBERON:0000947	95.46	gold quality
mucosa of stomach	UBERON:0001199	95.44	gold quality
adenohypophysis	UBERON:0002196	95.41	gold quality
cerebellar cortex	UBERON:0002129	95.35	gold quality
ascending aorta	UBERON:0001496	95.31	gold quality
thoracic aorta	UBERON:0001515	95.23	gold quality
left ovary	UBERON:0002119	95.18	gold quality
prefrontal cortex	UBERON:0000451	95.10	gold quality
right ovary	UBERON:0002118	94.72	gold quality
cingulate cortex	UBERON:0003027	94.61	gold quality
gastrocnemius	UBERON:0001388	94.60	gold quality
sural nerve	UBERON:0015488	94.56	gold quality
right lung	UBERON:0002167	94.54	gold quality
lower esophagus	UBERON:0013473	94.51	gold quality
descending thoracic aorta	UBERON:0002345	94.50	gold quality
anterior cingulate cortex	UBERON:0009835	94.50	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.50	gold quality
pituitary gland	UBERON:0000007	94.43	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.39
E-MTAB-10137	no	311.66

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

10 targets.

Target	Regulation
ERVW-1	Repression
FGF2	Repression
GCM1	Repression
IGF2	Unknown
MEF2A	Repression
SLC2A1	Activation
SLC2A4	Repression
SLIT2	Repression
WT1	Repression
YY1	Activation

Upstream regulators (CollecTRI, top): CAMK1

miRNA regulators (miRDB)

87 targeting HDAC5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-4739	99.84	65.25	1832

Literature-anchored findings (GeneRIF, showing 40)

• Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor (PMID:11929873)
• Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. (PMID:12019172)
• MITR, HDAC4, and HDAC5 associate with heterochromatin protein 1 (HP1), an adaptor protein that recognizes methylated lysines within histone tails and mediates transcriptional repression by recruiting histone methyltransferase (PMID:12242305)
• HDAC5 binds to Ca(2+)/calmodulin and inhibits MEF2a binding (PMID:12626519)
• ICP0 of herpes simplex virus Type 1 is able to overcome the HDAC5 amino-terminal- and MITR-induced MEF2A repression in gene reporter assays (PMID:15194749)
• The HDAC5, a class II HDAC involved in myogenesis, was not detected in the tissues. (PMID:15590418)
• G betagamma binds HDAC5 and inhibits its transcriptional co-repression activity (PMID:16221676)
• novel transcriptional pathway under the control of class II HDACs and suggest a role for these transcriptional repressors as signal-responsive regulators of antigen presentation (PMID:16236793)
• NO-dependent PP2A activation plays a key role in nuclear translocation of class II HDACs HDAC4 and HDAC5 (PMID:17975112)
• AMP-activated protein kinase (AMPK) regulates GLUT4 transcription through the histone deacetylase (HDAC)5 transcriptional repressor. (PMID:18184930)
• Chronic upregulation/activation of CaMKIID, and PKD in heart failure shifts HDAC5 out of the nucleus, derepressing transcription of hypertrophic genes. (PMID:18218981)
• Protein kinase D-HDAC5 pathway plays an important role in VEGF regulation of gene transcription and angiogenesis (PMID:18332134)
• These results indicate that HDAC4 and HDAC5 increase the transactivation function of HIF-1alpha by promoting dissociation of HIF-1alpha from FIH-1 and association with p300. (PMID:19071119)
• HDAC5 represses angiogenic genes, such as FGF2 and Slit2, which causally contribute to capillary-like sprouting of endothelial cells. (PMID:19351956)
• phosphorylation-dependent derepression of HDAC5 mediates flow-induced KLF2 and eNOS expression as well as flow anti-inflammation, and suggest that HDAC5 could be a potential therapeutic target for the prevention of atherosclerosis. (PMID:20042720)
• Findings identify HDAC5 as a substrate of PKA and reveal a cAMP/PKA-dependent pathway that controls HDAC5 nucleocytoplasmic shuttling and represses gene transcription. (PMID:20716686)
• differentiation-dependent GLUT4 gene expression in 3T3-L1 adipocytes is dependent on the nuclear concentration of a class II histone deacetylase (HDAC) protein, HDAC5 (PMID:21047791)
• Ser279 is a critical phosphorylation within the NLS involved in the nuclear import of HDAC5 (PMID:21081666)
• in addition to activation of protein kinase D isozymes by phosphorylating Ser744 and Ser748 at their activation sites, PKCdelta may also play a role in the regulation of HDAC5 by phosphorylation of Ser259 (PMID:21146494)
• Significantly increased methylation of the HDAC5 gene was associated with astrocytomas. (PMID:21508384)
• The results of this study suggested that suggest that HDAC5 provides a delayed braking mechanism on gene expression programs that support the development, but not expression, of cocaine reward behaviors. (PMID:22243750)
• HDAC5 in the maintenance/assembly of pericentric heterochromatin structure and demonstrate that class IIa HDAC5 can represent a potential target for anticancer therapies. (PMID:22301920)
• Loss of HDAC5 impairs memory function but has little impact in a transgenic mouse model of amyloid pathology. (PMID:22914591)
• The current study identified the class II deacetylase HDAC5 as a novel promoting factor of CTG*CAG expansions. (PMID:22941650)
• Data suggest that HDAC5 regulates muscle glucose metabolism and insulin action and that HDAC inhibitors can be used to modulate these parameters in muscle cells. (PMID:22991226)
• Dephosphorylation at a conserved SP motif governs cAMP sensitivity and nuclear localization of class IIa histone deacetylases HDAC4, 5 and 9 (PMID:23297420)
• Nuclear calcium signaling is a regulator of nuclear export of HDAC4 and HDAC5. (PMID:23364788)
• Data indicate there was a link between baseline viral load, age (40 years), IL-28B (rs12979860), HDAC2 (rs3778216), HDAC3 (rs976552) and HDAC5 (rs368328) with sustained virological response (SVR). (PMID:23615070)
• HDAC5 is essential for the length maintenance of long telomeres and its depletion is required for sensitization of cancer cells with long telomeres to chemotherapy. (PMID:23729589)
• findings show N-Myc upregulated HDAC5 expression in neuroblastoma cells; HDAC5 repressed NEDD4 gene expression,increased Aurora A gene expression and consequently upregulated N-Myc protein expression;data identify HDAC5 as a novel co-factor in N-Myc oncogenesis (PMID:23812427)
• At the molecular level, we demonstrated that HDAC5 promoted mRNA expression of twist 1, which has been reported as an oncogene (PMID:24092570)
• These findings suggest that HDAC5 is a key determinant of p53-mediated cell fate decisions in response to genotoxic stress. (PMID:24120667)
• we show that Stat3 binds to the promoter region of PTPN13 and promotes its activity through recruiting HDAC5. Thus, our results suggest a previously unknown Stat3-PTPN13 molecular network controlling squamous cell lung carcinoma development (PMID:24191246)
• In erythroid cells, pull down experiments identified the presence of a novel complex formed by HDAC5, GATA1, EKLF and pERK which was instead undetectable in cells of the megakaryocytic lineage. (PMID:24594363)
• HDAC5 promoted the Six1 expression. (PMID:24706304)
• In C2C12 myoblasts, recombinant human HDAC5 phosphorylation by PKD regulated the expression of diverse metabolic genes and glucose metabolism. (PMID:24732133)
• Studied phosphorylation sites within functional HDAC5 domains, including the deacetylation domain (DAC, Ser755), nuclear export signal (NES, Ser1108), and an acidic domain (AD, Ser611). (PMID:24920159)
• Data reveal a novel role of HDAC5 in modulating the KLF2 transcriptional activation and eNOS expression. (PMID:25096223)
• mRNA and protein levels of HDAC5 were up-regulated in human hepatocellular carcinoma. (PMID:25129440)
• These results suggest a strong regulatory function of HDAC5 in the pro-inflammatory response of macrophages. (PMID:26059794)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	hdac5	ENSDARG00000075139
mus_musculus	Hdac5	ENSMUSG00000008855
rattus_norvegicus	Hdac5	ENSRNOG00000020905
caenorhabditis_elegans		WBGENE00009657
caenorhabditis_elegans		WBGENE00009663
caenorhabditis_elegans		WBGENE00219378

Paralogs (10): HDAC9 (ENSG00000048052), HDAC7 (ENSG00000061273), HDAC4 (ENSG00000068024), HDAC6 (ENSG00000094631), HDAC10 (ENSG00000100429), HDAC1 (ENSG00000116478), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC3 (ENSG00000171720), HDAC2 (ENSG00000196591)

Protein

Protein identifiers

Histone deacetylase 5 — Q9UQL6 (reviewed: Q9UQL6)

Alternative names: Antigen NY-CO-9

All UniProt accessions (5): Q9UQL6, K7EJL4, K7EJL6, K7EJZ7, K7ES01

UniProt curated annotations — full annotation on UniProt →

Function. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation by repressing transcription of myocyte enhancer MEF2C. During muscle differentiation, it shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Serves as a corepressor of RARA and causes its deacetylation. In association with RARA, plays a role in the repression of microRNA-10a and thereby in the inflammatory response.

Subunit / interactions. Interacts with AHRR, BAHD1, BCOR, HDAC7, HDAC9, CTBP1, MEF2C, NCOR2, NRIP1, PHB2 and a 14-3-3 chaperone protein. Interacts with BCL6, DDIT3/CHOP, GRK5, KDM5B and MYOCD. Interacts with EP300 in the presence of TFAP2C. Interacts with ANKRA2. Interacts with CUL7 (as part of the 3M complex); negatively regulated by ANKRA2. Interacts with ZBTB7B; the interaction allows the recruitment of HDAC4 on CD8 loci for deacetylation and possible inhibition of CD8 genes expression. Interacts with RARA.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Ubiquitous.

Post-translational modifications. Phosphorylated by AMPK, CaMK1, SIK1 and PRKD1 at Ser-259 and Ser-498. The phosphorylation is required for the export to the cytoplasm and inhibition. Phosphorylated by the PKC kinases PKN1 and PKN2, impairing nuclear import. Phosphorylated by GRK5, leading to nuclear export of HDAC5 and allowing MEF2-mediated transcription. Ubiquitinated. Polyubiquitination however does not lead to its degradation.

Domain organisation. The nuclear export sequence mediates the shuttling between the nucleus and the cytoplasm.

Similarity. Belongs to the histone deacetylase family. HD type 2 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UQL6-1	1	yes
Q9UQL6-2	2
Q9UQL6-3	3

RefSeq proteins (3): NP_001015053, NP_001369322, NP_005465* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000286	HDACs	Family
IPR023696	Ureohydrolase_dom_sf	Homologous_superfamily
IPR023801	His_deacetylse_dom	Domain
IPR024643	Hist_deacetylase_Gln_rich_N	Domain
IPR037138	His_deacetylse_dom_sf	Homologous_superfamily
IPR046949	HDAC4/5/7/9	Family

Pfam: PF00850, PF12203

Catalyzed reactions (Rhea), 1 shown:

• N(6)-acetyl-L-lysyl-[histone] + H2O = L-lysyl-[histone] + acetate (RHEA:58196)

UniProt features (53 total): mutagenesis site 9, sequence conflict 9, region of interest 8, compositionally biased region 7, modified residue 7, binding site 4, splice variant 2, sequence variant 2, chain 1, active site 1, cross-link 1, helix 1, short sequence motif 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
5UWI	X-RAY DIFFRACTION	2.14
8Q9P	X-RAY DIFFRACTION	2.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UQL6-F1	64.14	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 833

Ligand- & substrate-binding residues (4): 696; 698; 704; 781

Post-translational modifications (8): 259, 292, 498, 533, 611, 661, 1108, 35

Mutagenesis-validated functional residues (9):

Position	Phenotype
259	reduces ampk- and camk-dependent phosphorylation and the subsequent nuclear export. abolishes nuclear export; when assoc
279	no effect.
291	does not affect phosphorylation by pkc.
292	abolishes phosphorylation by pkc.
498	reduces ampk- and camk-dependent phosphorylation and the subsequent nuclear export. abolishes nuclear export; when assoc
661	no effect.
713	no effect.
1086	reduces camk-dependent nuclear export.
1092	reduces camk-dependent nuclear export.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-350054	Notch-HLH transcription pathway
R-HSA-8943724	Regulation of PTEN gene transcription
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)

MSigDB gene sets: 322 (showing top): PID_HDAC_CLASSI_PATHWAY, REACTOME_SIGNALING_BY_NOTCH, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_COCAINE, GOBP_NEGATIVE_REGULATION_OF_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_INFLAMMATORY_RESPONSE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_B_CELL_ACTIVATION, GOBP_NEGATIVE_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_BLOOD_VESSEL_ENDOTHELIAL_CELL_MIGRATION, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_CELL_MIGRATION_INVOLVED_IN_SPROUTING_ANGIOGENESIS, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_STRIATED_MUSCLE_CELL_DIFFERENTIATION, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN

GO Biological Process (19): negative regulation of transcription by RNA polymerase II (GO:0000122), inflammatory response (GO:0006954), response to xenobiotic stimulus (GO:0009410), regulation of myotube differentiation (GO:0010830), negative regulation of myotube differentiation (GO:0010832), response to activity (GO:0014823), neuron differentiation (GO:0030182), B cell differentiation (GO:0030183), cellular response to insulin stimulus (GO:0032869), epigenetic regulation of gene expression (GO:0040029), B cell activation (GO:0042113), response to cocaine (GO:0042220), negative regulation of gene expression, epigenetic (GO:0045814), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), cellular response to lipopolysaccharide (GO:0071222), negative regulation of cell migration involved in sprouting angiogenesis (GO:0090051), chromatin organization (GO:0006325), negative regulation of macromolecule biosynthetic process (GO:0010558)

GO Molecular Function (16): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription activator activity (GO:0001216), transcription corepressor binding (GO:0001222), chromatin binding (GO:0003682), histone deacetylase activity (GO:0004407), protein kinase C binding (GO:0005080), protein lysine deacetylase activity (GO:0033558), identical protein binding (GO:0042802), histone deacetylase binding (GO:0042826), metal ion binding (GO:0046872), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), DNA-binding transcription factor binding (GO:0140297), histone deacetylase activity, hydrolytic mechanism (GO:0141221), transcription cis-regulatory region binding (GO:0000976), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (8): histone deacetylase complex (GO:0000118), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), cytosol (GO:0005829), nuclear speck (GO:0016607), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Signaling by NOTCH1	1
Signaling by NOTCH1 PEST Domain Mutants in Cancer	1
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	1
Generic Transcription Pathway	1
PTEN Regulation	1
Differentiation of T cells	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
myotube differentiation	2
positive regulation of DNA-templated transcription	2
binding	2
intracellular membrane-bounded organelle	2
cytoplasm	2
negative regulation of DNA-templated transcription	1
defense response	1
response to chemical	1
regulation of striated muscle cell differentiation	1
regulation of myotube differentiation	1
negative regulation of striated muscle cell differentiation	1
response to stimulus	1
cell differentiation	1
generation of neurons	1
lymphocyte differentiation	1
B cell activation	1
response to insulin	1
cellular response to peptide hormone stimulus	1
chromatin remodeling	1
regulation of gene expression	1
lymphocyte activation	1
response to alkaloid	1
response to oxygen-containing compound	1
negative regulation of gene expression	1
epigenetic regulation of gene expression	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
response to lipopolysaccharide	1
cellular response to molecule of bacterial origin	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
cell migration involved in sprouting angiogenesis	1
negative regulation of blood vessel endothelial cell migration	1
regulation of cell migration involved in sprouting angiogenesis	1
cellular component organization	1
macromolecule biosynthetic process	1

Protein interactions and networks

STRING

2890 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HDAC5	NR2E1	Q9Y466	864
HDAC5	MEF2C	Q06413	860
HDAC5	MEF2D	Q14814	841
HDAC5	NCOR1	O75376	821
HDAC5	NCOR2	Q9Y618	751
HDAC5	MEF2A	Q02078	743
HDAC5	H3C1	P02295	706
HDAC5	H3-3A	P06351	706
HDAC5	H3-4	Q16695	706
HDAC5	H3-7	Q5TEC6	706
HDAC5	H3-5	Q6NXT2	706
HDAC5	H3C14	Q71DI3	706
HDAC5	SIK1	P57059	693
HDAC5	BAHD1	Q8TBE0	684
HDAC5	GATA3	P23771	636
HDAC5	EP300	Q09472	636

IntAct

83 interactions, top by confidence:

A	B	Type	Score
YWHAZ	HDAC5	psi-mi:“MI:0915”(physical association)	0.800
HDAC5	YWHAE	psi-mi:“MI:0914”(association)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAB	BLTP3B	psi-mi:“MI:0914”(association)	0.610
ANKRA2	HDAC5	psi-mi:“MI:0407”(direct interaction)	0.590
HDAC5	HDAC5	psi-mi:“MI:0915”(physical association)	0.560
LMO2	HDAC5	psi-mi:“MI:0915”(physical association)	0.560
RUNX3	EP300	psi-mi:“MI:0914”(association)	0.560
MEF2C	HDAC5	psi-mi:“MI:0915”(physical association)	0.550
SFN	HDAC5	psi-mi:“MI:0915”(physical association)	0.550
HDAC5	Grk5	psi-mi:“MI:0915”(physical association)	0.540
HDAC5	Grk5	psi-mi:“MI:0407”(direct interaction)	0.540
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
LTBR	ZNF724	psi-mi:“MI:0914”(association)	0.530
BRMS1	HDAC5	psi-mi:“MI:0915”(physical association)	0.520
HDAC5	BRMS1	psi-mi:“MI:0915”(physical association)	0.520
HDAC5	ICP0	psi-mi:“MI:0915”(physical association)	0.520
RUNX3	HDAC5	psi-mi:“MI:0915”(physical association)	0.500
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
YWHAQ	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
RUNX3	CCND1	psi-mi:“MI:0914”(association)	0.460
HDAC5	H4C16	psi-mi:“MI:0197”(deacetylation reaction)	0.440

BioGRID (489): HDAC5 (Affinity Capture-Western), DDIT3 (Affinity Capture-Western), HDAC5 (Affinity Capture-Western), HDAC5 (Reconstituted Complex), Cbx5 (Affinity Capture-Western), HDAC5 (Reconstituted Complex), HDAC5 (Reconstituted Complex), HDAC5 (Reconstituted Complex), HDAC5 (Affinity Capture-MS), YWHAE (Affinity Capture-Western), HDAC5 (Affinity Capture-MS), ANKRA2 (Affinity Capture-Western), CUL7 (Affinity Capture-Western), HDAC5 (Affinity Capture-Western), HDAC5 (Affinity Capture-MS)

ESM2 similar proteins: A0A571BF63, A0A8M9QN10, A2ARM1, A2CI97, A3KNA7, A4D1P6, A9C3W3, B2RYI0, E9Q7E2, F1QNV4, O95475, P49848, P56524, P70302, P83093, P84903, Q0VDN7, Q12769, Q12772, Q13586, Q2HJE1, Q32N92, Q3T1I5, Q3U1N2, Q3UGY8, Q58CP9, Q58HI1, Q5E9R0, Q5R902, Q5ZLL7, Q60429, Q62311, Q63801, Q6GQ26, Q6NZM9, Q6P4L9, Q6P4R8, Q6PIJ4, Q6ZPR5, Q7TMQ7

Diamond homologs: A0A8I6GM68, D2HBJ8, F1QCV2, O17323, O27262, O30107, P28606, P38748, P53973, P56523, P56524, P72702, P83038, Q09440, Q0V9G5, Q20296, Q2QWU2, Q3JUN4, Q54QE6, Q569C4, Q57955, Q5A960, Q5R902, Q5XGZ2, Q613L4, Q6NTR6, Q6NZM9, Q6P3E7, Q6P9L4, Q70CQ1, Q70I53, Q7Z569, Q7ZUM8, Q80ZH1, Q8C2B3, Q8C2S0, Q8GXJ1, Q8LRK8, Q8RX28, Q8WUI4

SIGNOR signaling

43 interactions.

A	Effect	B	Mechanism
HDAC5	down-regulates	RUNX2	deacetylation
PRKAA1	down-regulates	HDAC5	phosphorylation
AURKB	down-regulates	HDAC5	phosphorylation
PRKACA	“up-regulates activity”	HDAC5	phosphorylation
PRKD1	down-regulates	HDAC5	phosphorylation
AMPK	down-regulates	HDAC5	phosphorylation
HDAC5	“down-regulates activity”	RUNX2	deacetylation
CAMK4	down-regulates	HDAC5	phosphorylation
BCOR	“up-regulates activity”	HDAC5	binding
BCORL1	“up-regulates activity”	HDAC5	binding
PRKCD	“down-regulates activity”	HDAC5	phosphorylation
GRK5	“down-regulates activity”	HDAC5	phosphorylation
HDAC5	down-regulates	MEF2A	binding
HDAC5	down-regulates	MEF2C	binding
HDAC5	down-regulates	MEF2D	binding
CAMK1	down-regulates	HDAC5	phosphorylation
CAMK2G	down-regulates	HDAC5	phosphorylation
14-3-3	down-regulates	HDAC5	binding
DYRK1B	“down-regulates activity”	HDAC5	phosphorylation
PRKCA	“down-regulates activity”	HDAC5	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 65 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	9	120.9×	3e-15
Activation of BAD and translocation to mitochondria	7	106.6×	2e-11
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	94.0×	4e-11
Activation of BH3-only proteins	7	69.5×	3e-10
RHO GTPases activate PKNs	8	50.8×	2e-10
Intrinsic Pathway for Apoptosis	7	41.0×	2e-08
FOXO-mediated transcription	6	40.3×	3e-07
Expression of BMAL (ARNTL), CLOCK, and NPAS2	5	29.3×	1e-05

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	7	43.5×	1e-07
intracellular protein localization	9	16.0×	1e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

173 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	131
Likely benign	7
Benign	9

Top pathogenic / likely-pathogenic (0)

SpliceAI

4246 predictions. Top by Δscore:

Variant	Effect	Δscore
17:44078661:TTTGC:T	acceptor_gain	1.0000
17:44078662:TTGC:T	acceptor_gain	1.0000
17:44078663:TGC:T	acceptor_gain	1.0000
17:44078664:GC:G	acceptor_gain	1.0000
17:44078664:GCCT:G	acceptor_loss	1.0000
17:44078665:CC:C	acceptor_gain	1.0000
17:44078666:C:CC	acceptor_gain	1.0000
17:44078666:C:G	acceptor_loss	1.0000
17:44078668:G:C	acceptor_gain	1.0000
17:44078673:C:CT	acceptor_gain	1.0000
17:44078674:G:T	acceptor_gain	1.0000
17:44078756:C:CA	donor_gain	1.0000
17:44078784:T:TA	donor_gain	1.0000
17:44078789:A:AC	donor_gain	1.0000
17:44078790:C:CC	donor_gain	1.0000
17:44078790:CG:C	donor_gain	1.0000
17:44078790:CGCA:C	donor_gain	1.0000
17:44078793:A:AC	donor_gain	1.0000
17:44078794:C:CC	donor_gain	1.0000
17:44078794:CT:C	donor_gain	1.0000
17:44078813:T:A	donor_gain	1.0000
17:44078875:TGCAG:T	acceptor_gain	1.0000
17:44078877:CAG:C	acceptor_gain	1.0000
17:44078880:C:CC	acceptor_gain	1.0000
17:44078880:C:T	acceptor_loss	1.0000
17:44078884:C:CT	acceptor_gain	1.0000
17:44078885:A:T	acceptor_gain	1.0000
17:44079290:G:C	acceptor_gain	1.0000
17:44080102:CTTA:C	donor_loss	1.0000
17:44080103:TTA:T	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000038438 (17:44097747 G>A), RS1000107700 (17:44122637 C>G), RS1000122668 (17:44117360 C>A,T), RS1000169458 (17:44092896 A>T), RS1000171406 (17:44114445 G>A,C,T), RS1000196186 (17:44077887 C>G), RS1000268135 (17:44088851 C>T), RS1000316024 (17:44086980 TGGGGGC>T,TGGGGGCGGGGGC), RS1000359216 (17:44125148 G>A), RS1000479772 (17:44119207 G>A), RS1000553531 (17:44119563 C>A,T), RS1000592524 (17:44099598 C>T), RS1000607809 (17:44093201 T>C), RS1000645913 (17:44092665 G>A,T), RS1000680335 (17:44111346 G>A,C,T)

Disease associations

OMIM: gene MIM:605315 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST000494_8	Bone mineral density (spine)	4.000000e-06
GCST000495_10	Bone mineral density (hip)	2.000000e-08
GCST006288_290	Heel bone mineral density	6.000000e-17
GCST006288_359	Heel bone mineral density	3.000000e-06
GCST006288_57	Heel bone mineral density	6.000000e-14
GCST006979_821	Heel bone mineral density	2.000000e-40
GCST008103_24	Bipolar disorder	2.000000e-08
GCST010241_293	Apolipoprotein A1 levels	8.000000e-09
GCST010242_138	HDL cholesterol levels	2.000000e-12
GCST011102_19	Bipolar disorder	3.000000e-08
GCST012465_26	Bipolar disorder	3.000000e-10
GCST90002395_257	Mean platelet volume	4.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (5): CHEMBL2093865 (PROTEIN FAMILY), CHEMBL2563 (SINGLE PROTEIN), CHEMBL3038483 (PROTEIN FAMILY), CHEMBL4630737 (PROTEIN-PROTEIN INTERACTION), CHEMBL6195544 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

30 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 476,054 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL118	CELECOXIB	4	112,844
CHEMBL1469	PHENYLBUTANOIC ACID	4	37,081
CHEMBL1746	SODIUM PHENYLBUTYRATE	4	5,577
CHEMBL343448	ROMIDEPSIN	4	12,963
CHEMBL408513	BELINOSTAT	4	7,765
CHEMBL483254	PANOBINOSTAT	4	11,666
CHEMBL98	VORINOSTAT	4	50,361
CHEMBL1213492	GIVINOSTAT	4	2,827
CHEMBL487253	BENDAMUSTINE	4	30,877
CHEMBL140	CURCUMIN	3	93,882
CHEMBL145	CAFFEIC ACID	3	36,305
CHEMBL1851943	PRACINOSTAT	3	1,998
CHEMBL235191	TACEDINALINE	3	2,950
CHEMBL27759	ENTINOSTAT	3	6,584
CHEMBL3621988	TUCIDINOSTAT	3	2,182
CHEMBL2103863	ABEXINOSTAT	3	2,195
CHEMBL51085	EBSELEN	3	13,237
CHEMBL1801250	NANATINOSTAT	2	754
CHEMBL191482	AR-42	2	2,061
CHEMBL284616	CHLOROGENIC ACID	2	41,945
CHEMBL356066	DACINOSTAT	2
CHEMBL3622533	FIMEPINOSTAT	2
CHEMBL2105763	QUISINOSTAT	2
CHEMBL2364628	RICOLINOSTAT	2
CHEMBL3989941	TINOSTAMUSTINE	2
CHEMBL353581	PYROXAMIDE	1
CHEMBL598797	CUDC-101	1
CHEMBL609583	R-306465	1
CHEMBL96	GAMMA-AMINOBUTYRIC ACID	1
CHEMBL99	TRICHOSTATIN	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — 3.5.1.- Histone deacetylases (HDACs)

Most potent curated ligand interactions (15 total), top 15:

Ligand	Action	Affinity	Parameter
quisinostat	Inhibition	8.43	pIC50
CUDC-101	Inhibition	7.94	pIC50
pracinostat	Inhibition	7.33	pIC50
TMP269	Inhibition	7.01	pIC50
belinostat	Inhibition	6.76	pKi
CHR-3996	Inhibition	6.7	pIC50
trichostatin A	Inhibition	6.59	pKi
martinostat	Inhibition	6.45	pIC50
dacinostat	Inhibition	6.38	pKi
romidepsin	Inhibition	6.26	pKi
givinostat	Inhibition	6.22	pKi
scriptaid	Inhibition	6.0	pKi
KA1010	Inhibition	5.96	pIC50
vorinostat	Inhibition	5.44	pKi
SS-208	Inhibition	5.16	pIC50

Binding affinities (BindingDB)

42 measured of 53 human assays (54 total across all organisms); most potent 42 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(E)-N-hydroxy-3-[4-[[2-(1-methylindol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide	IC50	0.2 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
(E)-3-[4-[[1-adamantylmethyl(methyl)amino]methyl]phenyl]-N-hydroxyprop-2-enamide	IC50	0.3 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
(E)-3-[4-[(1-adamantylmethylamino)methyl]-3-fluorophenyl]-N-hydroxyprop-2-enamide	IC50	0.78 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
(E)-3-[4-[[1-adamantylmethyl(methyl)amino]methyl]-3-fluorophenyl]-N-hydroxyprop-2-enamide	IC50	0.78 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
N-hydroxy-6-(8-methoxy-6,11,11-trioxobenzo[b][1,4]benzothiazepin-5-yl)hexanamide	IC50	0.8 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
Panobinostat	IC50	1 nM
N-hydroxy-6-(8-methoxy-6-oxobenzo[b][1,4]benzothiazepin-5-yl)hexanamide	IC50	1.2 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
(E)-3-[4-[(cyclohexylmethylamino)methyl]phenyl]-N-hydroxyprop-2-enamide	IC50	1.8 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
BRD2492	IC50	2 nM
(E)-3-[2-butyl-1-[2-(dimethylamino)ethyl]benzimidazol-5-yl]-N-hydroxyprop-2-enamide	IC50	4.7 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
CHEBI:46024	IC50	4.9 nM
(E)-N-hydroxy-3-[3-[methyl(2-phenylethyl)sulfamoyl]phenyl]prop-2-enamide	IC50	5 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
R-TSA	IC50	5.76 nM
HDAC inhibitor, Compound 2	IC50	7.93 nM
HDAC inhibitor, Compound 1	IC50	10.1 nM
(E)-N-hydroxy-3-[3-[methyl(phenyl)sulfamoyl]phenyl]prop-2-enamide	IC50	17.8 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
(E)-3-[3-[(1-adamantylamino)methyl]phenyl]-N-hydroxyprop-2-enamide	IC50	24 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)nonyl]acetamide	IC50	26 nM
3-(furan-3-yl)-N-[[4-(hydroxycarbamoyl)phenyl]methyl]-5-(4-hydroxyphenyl)-1H-pyrrole-2-carboxamide	IC50	49.9 nM	US-8685992: Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers
6-[[1-adamantylmethyl(methyl)amino]methyl]-N-hydroxy-3,4-dihydronaphthalene-2-carboxamide	IC50	55.8 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide	IC50	59 nM
N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]-3-(4-hydroxyphenyl)-5-thiophen-3-yl-1H-pyrrole-2-carboxamide	IC50	71 nM	US-8685992: Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers
N-hydroxy-7-[pyridin-2-yl(quinolin-2-yl)amino]heptanamide	IC50	71 nM	US-8748458: Scriptaid isosteres and their use in therapy
3-(4-methoxyphenyl)-5-phenyl-N-[[4-(2-sulfanylethylcarbamoyl)phenyl]methyl]-1H-pyrrole-2-carboxamide	IC50	84.2 nM	US-8685992: Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers
MGCD-0103	IC50	102 nM	US-9409858: Selective histone deactylase 6 inhibitors
(E)-N-Hydroxy-3-phenyl-acrylamide	IC50	133 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
N-hydroxy-4-[(3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)methyl]benzamide	IC50	175 nM	US-10011611: Histone deacetylase inhibitors and methods for use thereof
N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]-3-(furan-3-yl)-5-(4-hydroxyphenyl)-1H-pyrrole-2-carboxamide	IC50	184 nM	US-8685992: Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers
S-TSA	IC50	206 nM
(E)-3-[4-[[1-adamantylmethyl(2-fluoroethyl)amino]methyl]phenyl]-N-hydroxyprop-2-enamide	IC50	221 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
MS-275	IC50	243 nM
3-(4-fluorophenyl)-N-[[4-(hydroxycarbamoyl)phenyl]methyl]-5-pyridin-3-yl-1H-pyrrole-2-carboxamide	IC50	332 nM	US-8685992: Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers
Octanedioic acid adamantan-1-ylamide hydroxyamide	IC50	420 nM
7-(dipyridin-2-ylamino)-N-hydroxyheptanamide	IC50	458 nM	US-8748458: Scriptaid isosteres and their use in therapy
(S)-Benzyl (6-acetamido-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxohexan-2-yl)carbamate, 21	IC50	643 nM
N-acetyldinaline	IC50	900 nM
(S)-6-acetamido-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-N-(4-methyl-2-oxo-2H-chromen-7-yl)hexanamide, 3	IC50	1180 nM
N’-(2-aminophenyl)-N-(4-methylphenyl)heptanediamide	IC50	2000 nM	US-9265734: Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
5-chloranyl-7-[(4-ethylpiperazin-1-yl)-pyridin-3-yl-methyl]quinolin-8-ol	IC50	2390 nM
2-ethyl-1-[(3R)-1-[(5-methoxy-1H-1,3-benzodiazol-2-yl)carbonyl]pyrrolidin-3-yl]-1H-1,3-benzodiazole	IC50	4200 nM
N-(4-{(2R,4R,6S)-4-{[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanyl]methyl}-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl}phenyl)-N -hydroxyoctanediamide	IC50	16400 nM	US-9249087: HDAC inhibitors and therapeutic methods using the same
CHEMBL3235790	IC50	120000 nM

ChEMBL bioactivities

3598 potent at pChembl≥5 of 3970 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.77	IC50	0.17	nM	CHEMBL5433552
9.70	IC50	0.2	nM	CHEMBL2371007
9.70	IC50	0.2	nM	CHEMBL5395502
9.70	IC50	0.2	nM	CHEMBL1793811
9.70	IC50	0.2	nM	CHEMBL1793991
9.70	IC50	0.2	nM	CHEMBL1793985
9.52	IC50	0.3	nM	CHEMBL2370998
9.52	IC50	0.3	nM	CHEMBL5199116
9.52	IC50	0.3	nM	CHEMBL5170036
9.52	IC50	0.3	nM	CHEMBL1793822
9.46	IC50	0.35	nM	VORINOSTAT
9.40	IC50	0.4	nM	CHEMBL2371000
9.40	IC50	0.4	nM	CHEMBL1793816
9.15	Ki	0.7	nM	PANOBINOSTAT
9.08	IC50	0.83	nM	PANOBINOSTAT
9.05	IC50	0.9	nM	CHEMBL605110
9.02	IC50	0.95	nM	CHEMBL595479
9.00	IC50	1	nM	CHEMBL3758184
9.00	IC50	1	nM	APICIDIN
9.00	IC50	1	nM	CHEMBL2371003
9.00	IC50	1	nM	ROMIDEPSIN
9.00	IC50	1	nM	CHEMBL4467135
9.00	IC50	1	nM	VORINOSTAT
9.00	IC50	1	nM	CHEMBL595711
9.00	IC50	1	nM	CHEMBL595910
9.00	IC50	1	nM	CHEMBL1793947
9.00	IC50	1	nM	CHEMBL1793810
9.00	IC50	1	nM	CHEMBL1793823
8.99	IC50	1.03	nM	CHEMBL1214760
8.98	IC50	1.05	nM	CHEMBL594544
8.92	IC50	1.2	nM	CHEMBL3692689
8.92	IC50	1.2	nM	CHEMBL604796
8.92	IC50	1.2	nM	CHEMBL608416
8.92	IC50	1.2	nM	CHEMBL594544
8.89	IC50	1.3	nM	CHEMBL1793992
8.85	IC50	1.4	nM	CHEMBL99661
8.85	IC50	1.42	nM	TRICHOSTATIN
8.82	IC50	1.5	nM	TRICHOSTATIN
8.82	IC50	1.5	nM	CHEMBL5280445
8.82	IC50	1.5	nM	CHEMBL594743
8.82	IC50	1.5	nM	CHEMBL593846
8.82	IC50	1.5	nM	CHEMBL594542
8.77	IC50	1.7	nM	CHEMBL595908
8.74	IC50	1.8	nM	CHEMBL478727
8.74	IC50	1.8	nM	CHEMBL26159
8.74	IC50	1.8	nM	CHEMBL595910
8.72	IC50	1.9	nM	CHEMBL477093
8.70	IC50	2	nM	CHEMBL99392
8.70	IC50	2	nM	CHEMBL150237
8.70	IC50	2	nM	CHEMBL4228565

PubChem BioAssay actives

2442 with measured affinity, of 6100 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-hydroxy-2-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]-1,3-thiazole-5-carboxamide	1941741: Inhibition of HDAC (unknown origin)	ic50	0.0001	uM
7-[4-[[4-[3-(tert-butylsulfamoyl)anilino]-5-methylpyrimidin-2-yl]amino]-2-fluorophenoxy]-N-hydroxyheptanamide	2031064: Inhibition of HDAC in human HeLa cells nuclear extract incubated for 30 mins by multiplate reader analysis	ic50	0.0002	uM
7-[4-[[4-[3-(tert-butylsulfamoyl)anilino]-5-methylpyrimidin-2-yl]amino]phenoxy]-N-hydroxyheptanamide	2031064: Inhibition of HDAC in human HeLa cells nuclear extract incubated for 30 mins by multiplate reader analysis	ic50	0.0002	uM
(9S,12R)-3-[(2S)-butan-2-yl]-9-(6-hydroxy-5-oxoheptyl)-6-[(1-methoxyindol-3-yl)methyl]-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	1847765: Inhibition of HDAC (unknown origin)	ic50	0.0003	uM
(9S,12R)-3-[(2S)-butan-2-yl]-6-(1H-indol-3-ylmethyl)-9-(5-oxoheptyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	1847765: Inhibition of HDAC (unknown origin)	ic50	0.0003	uM
(3S,6S,9S,12R)-3-[(2S)-butan-2-yl]-9-(7-hydroxy-6-oxooctyl)-6-[(1-methoxyindol-3-yl)methyl]-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	90356: Inhibitory concentration against human Histone deacetylase in Hela cells	ic50	0.0003	uM
N-hydroxy-2-[4-[(E)-1-hydroxy-4-(4-phenylphenyl)but-3-en-2-yl]piperazin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0009	uM
N-hydroxy-2-[4-[(E)-1-hydroxy-4-(4-methoxyphenyl)but-3-en-2-yl]piperazin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0009	uM
N-hydroxy-2-[4-[(E)-1-hydroxy-4-phenylbut-3-en-2-yl]piperazin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0010	uM
2-[4-[(E)-4-(4-fluorophenyl)-1-hydroxybut-3-en-2-yl]piperazin-1-yl]-N-hydroxypyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0010	uM
(3S,6R,9S,12R)-3-[(2S)-butan-2-yl]-6-[(1-methoxyindol-2-yl)methyl]-9-(6-oxooctyl)-1,4,10-triazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	1622995: Inhibition of HDAC (unknown origin)	ic50	0.0010	uM
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetrazacyclotridec-5-yl]hexanamide	447991: Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorimetric assay	ic50	0.0010	uM
N-hydroxy-2-[4-[(E)-1-hydroxy-4-(4-methylphenyl)but-3-en-2-yl]piperazin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0010	uM
6-[(5S,8S,11R)-11-[(2S)-butan-2-yl]-8-(1H-indol-2-ylmethyl)-3,6,9,13-tetraoxo-1,4,7,10-tetrazacyclotridec-5-yl]-N-hydroxyhexanamide	487230: Inhibition of HDAC in human HeLa cells	ic50	0.0010	uM
7-[4-[4-[[[(2S,3R,4S,6R)-2-[[(2R,4R,5R,6R,8R,11R,12S,19R,20R)-11-ethyl-4-methoxy-2,4,6,8,12,19-hexamethyl-7,9,14-trioxo-10,13-dioxa-15,18-diazatricyclo[10.6.2.015,20]icos-1(18)-en-5-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]triazol-1-yl]-N-hydroxyheptanamide	499799: Inhibition of HDAC in human HeLa cell nuclear extracts	ic50	0.0010	uM
(E)-N-hydroxy-3-[4-oxo-1’-(2-phenylethyl)spiro[3H-chromene-2,3’-piperidine]-6-yl]prop-2-enamide	1273866: Inhibition of HDAC in human HeLa cells nuclear extract using Fluor de lys as substrate after 15 mins by fluorometric analysis	ic50	0.0010	uM
2-[4-[(E)-4-(3-fluorophenyl)-1-hydroxybut-3-en-2-yl]piperazin-1-yl]-N-hydroxypyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0012	uM
2-[4-[(E)-4-(4-chlorophenyl)-1-hydroxybut-3-en-2-yl]piperazin-1-yl]-N-hydroxypyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0012	uM
N’-hydroxy-N-[(2R)-4-(methylamino)-3-oxo-1-phenylbutan-2-yl]octanediamide	90195: Concentration required to inhibit Histone Deacetylase (HDAC) from K562 erythroleukemia cells	ic50	0.0014	uM
(2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide	1273502: Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay	ic50	0.0014	uM
N-hydroxy-2-[4-(naphthalen-2-ylmethyl)piperazin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0015	uM
N-hydroxy-2-[4-[(E)-1-methoxy-4-phenylbut-3-en-2-yl]piperazin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0015	uM
N-hydroxy-2-[4-[[[(E)-1-hydroxy-4-phenylbut-3-en-2-yl]amino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0015	uM
N-hydroxy-2-[4-[(E)-4-phenylbut-3-en-2-yl]piperazin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0017	uM
N-hydroxy-6-[4-(6-methoxynaphthalen-2-yl)triazol-1-yl]hexanamide	382342: Inhibition of human HDAC in HeLa cells by flour de lys assay	ic50	0.0018	uM
N-hydroxy-6-[4-(3-phenylphenyl)triazol-1-yl]hexanamide	382342: Inhibition of human HDAC in HeLa cells by flour de lys assay	ic50	0.0019	uM
2-[2-[2-[[(2E)-3-(3-bromo-4-hydroxyphenyl)-2-hydroxyiminopropanoyl]amino]ethyldisulfanyl]ethylamino]-2-oxoacetic acid	90530: Inhibitory concentration against isolated Histone deacetylase	ic50	0.0020	uM
(3S,6S,9S,12R)-3-[(2S)-butan-2-yl]-6-(1H-indol-3-ylmethyl)-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	81887: Inhibitory activity against histone deacetylase (HDAC) enzyme derived from partially purified extracts of human HeLa cells using [3H]11 as radioligand	ic50	0.0020	uM
6-[4-[[5-chloro-4-(4-chloroanilino)pyrimidin-2-yl]amino]pyrazol-1-yl]-N-hydroxyhexanamide	1550094: Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	ic50	0.0020	uM
7-[4-[[5-chloro-4-(4-chloroanilino)pyrimidin-2-yl]amino]pyrazol-1-yl]-N-hydroxyheptanamide	1550094: Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	ic50	0.0020	uM
4-[(E)-3-[[(2S)-1-(4-bromoanilino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-oxoprop-1-enyl]-N-hydroxybenzamide	1390020: Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	ic50	0.0020	uM
4-[(E)-3-[[(2S)-1-(4-fluoroanilino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-oxoprop-1-enyl]-N-hydroxybenzamide	1390020: Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay	ic50	0.0020	uM
2-(6-ethoxy-3-pyridinyl)-N-[7-(hydroxyamino)-7-oxoheptyl]-9-(2-methoxy-3-pyridinyl)-8-oxo-7H-purine-6-carboxamide	2079009: Inhibition of HDAC in human HeLa cells nuclear extract	ic50	0.0020	uM
2-[4-[(E)-4-(2-fluorophenyl)-1-hydroxybut-3-en-2-yl]piperazin-1-yl]-N-hydroxypyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0020	uM
N-hydroxy-7-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]heptanamide	316872: Inhibition of HDAC from human K562 cells	ic50	0.0021	uM
N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide	1236447: Inhibition of human HDAC5	ki	0.0021	uM
N-hydroxy-6-[4-(4-methoxyphenyl)triazol-1-yl]hexanamide	382342: Inhibition of human HDAC in HeLa cells by flour de lys assay	ic50	0.0021	uM
tert-butyl (8R,9R,12S)-12-[[6-(hydroxyamino)-6-oxohexyl]carbamoyl]-9-(2-methylpropyl)-2-oxa-11-azabicyclo[12.2.2]octadeca-1(16),14,17-triene-8-carboxylate	90195: Concentration required to inhibit Histone Deacetylase (HDAC) from K562 erythroleukemia cells	ic50	0.0021	uM
N-hydroxy-6-(4-quinolin-2-yltriazol-1-yl)hexanamide	382342: Inhibition of human HDAC in HeLa cells by flour de lys assay	ic50	0.0021	uM
N-hydroxy-2-[4-[(E)-1-hydroxy-4-[4-(trifluoromethyl)phenyl]but-3-en-2-yl]piperazin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0021	uM
6-[4-(4-bromoanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyhexanamide	1720096: Inhibition of HDAC (unknown origin)	ic50	0.0022	uM
7-[4-(4-bromoanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide	1275247: Inhibition of HDAC in human HeLa cell nuclear extracts preincubated for 15 mins followed by addition of Fluor de Lys as substrate for 1 hr by fluorometric assay	ic50	0.0022	uM
N-hydroxy-6-[4-(4-pyridin-4-ylphenyl)triazol-1-yl]hexanamide	382342: Inhibition of human HDAC in HeLa cells by flour de lys assay	ic50	0.0023	uM
N-hydroxy-7-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]heptanamide	316872: Inhibition of HDAC from human K562 cells	ic50	0.0025	uM
7-[5-(4-bromophenyl)-1,3-oxazol-2-yl]-N-hydroxyheptanamide	316872: Inhibition of HDAC from human K562 cells	ic50	0.0027	uM
(E)-N-hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylsulfamoyl]phenyl]prop-2-enamide	1187258: Inhibition of HDAC in human HeLa cells nuclear extracts incubated for 30 mins by fluorescent assay	ic50	0.0028	uM
6-[4-(2,4-dichloroanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyhexanamide	1256443: Inhibition of human HDAC in HeLa cell nuclear extract by fluorometric assay using Fluor de Lys substrate	ic50	0.0028	uM
7-[4-(2,4-dichloroanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide	1915571: Inhibition of HDAC (unknown origin)	ic50	0.0028	uM
N-hydroxy-7-[4-(2-methylphenyl)triazol-1-yl]heptanamide	456795: Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay	ic50	0.0028	uM
7-[4-[[5-chloro-4-(4-fluoroanilino)pyrimidin-2-yl]amino]pyrazol-1-yl]-N-hydroxyheptanamide	1550094: Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence assay	ic50	0.0030	uM

CTD chemical–gene interactions

69 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	5
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	3
Air Pollutants	affects cotreatment, decreases expression, increases abundance, affects expression	3
Estradiol	decreases expression, decreases reaction	3
dorsomorphin	affects localization, decreases reaction, increases phosphorylation, affects cotreatment, decreases expression	2
Resveratrol	decreases reaction, increases phosphorylation, affects cotreatment, decreases expression, affects binding	2
Arsenic	affects methylation, affects cotreatment, decreases expression, increases abundance	2
Cisplatin	affects cotreatment, increases expression	2
Lipopolysaccharides	increases expression, affects cotreatment, decreases reaction, affects response to substance, decreases expression (+3 more)	2
Nickel	decreases expression	2
Ozone	affects cotreatment, decreases expression, increases abundance, affects expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
aristolochic acid I	increases expression	1
GSK-J4	increases expression	1
afuresertib	increases expression	1
FR900359	affects phosphorylation	1
Batroxase, Bothrops atrox	increases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
terbufos	increases methylation	1
sulforaphane	decreases expression	1
cupric chloride	decreases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects response to substance	1
epigallocatechin gallate	decreases expression	1
KN 62	increases phosphorylation, affects localization, decreases reaction	1
perfluorooctane sulfonic acid	increases expression	1
pterostilbene	increases expression, increases phosphorylation, affects binding, decreases reaction, affects reaction	1
platycodin D	increases phosphorylation, affects localization, decreases reaction	1

ChEMBL screening assays

1686 unique, capped per target: 1670 binding, 11 admet, 4 functional, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1003756	Binding	Inhibition of HDAC in human NB4 cells assessed as induction of histone H3 acetylation after 6 hrs by Western blot analysis	Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents. — Bioorg Med Chem Lett
CHEMBL4346553	ADMET	Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis. — J Med Chem
CHEMBL5049470	Functional	In vivo inhibition of HDAC in HEL cells xenografted in BALB/C mouse assessed as upregulation of caspase-9 levels at 5 to 10 mg/kg by immunohistochemical staining method	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy. — J Med Chem

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8H9	Abcam HCT 116 HDAC5 KO	Cancer cell line	Male
CVCL_B8WM	Abcam MCF-7 HDAC5 KO	Cancer cell line	Female
CVCL_B9JJ	Abcam A-549 HDAC5 KO	Cancer cell line	Male
CVCL_SR11	HAP1 HDAC5 (-) 1	Cancer cell line	Male
CVCL_SR12	HAP1 HDAC5 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome